---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-035160"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:03:41.075752+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sangamo posts Q2 net loss $0.18/sh, cash $27.8M; signs Genentech deal for up to $1.9B

## Summary
- Signed global license with Genentech for zinc finger repressors targeting tau and STAC-BBB capsid; $50M near-term, up to $1.9B milestones plus royalties.
- Q2 net loss $36.1M ($0.18/sh) vs $114.5M ($0.66); revenue $0.3M down from $6.8M.
- Cash $27.8M at June 30; with Genentech $50M, runway into Q1 2025.
- Pfizer's Phase 3 hemophilia A gene therapy met primary endpoint; Sangamo eligible for up to $220M milestones and 14-20% royalties.
- Fabry disease: 33 patients dosed, 17 off ERT; eGFR improvement observed.

## SEC filing metadata
- accession: 0001628280-24-035160
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828024035160/0001628280-24-035160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828024035160/sgmo-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-035160
- JSON: https://secwatch.observer/filing/0001628280-24-035160.json
- Plain text: https://secwatch.observer/filing/0001628280-24-035160.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.